Baptiste Tesson Author Auteur Baptiste is studying biology at the École Normale Supérieure de Lyon and bioengineering at the École Polytechnique Fédérale de Lausanne. He worked on the optimization of Cas9 as a tool for genome editing and on the emergence of blood stem cells in the zebrafish. He currently works on the patterning of the muscles, also in the zebrafish. He plans on doing a PhD in developmental biology. More about the Long Long Life team Baptiste étudie la biologie à l’École Normale Supérieure de Lyon et la bioingénierie à l’École Polytechnique Fédérale de Lausanne. Il a travaillé sur l’optimisation de la protéine Cas9 comme outil de modification de génomes et sur le développement des cellules souches du sang chez le poisson zèbre et travaille actuellement sur la mise en place des muscles chez le même animal. Il projette de réaliser un doctorat axé vers le développement animal. En savoir plus sur l’équipe de Long Long Life

References:

[1] Virally, M., Laloi-Michelin, M., Kevorkian, J. P., Bitu, J., & Guillausseau, P. J. (2011). Specificities of type 2 diabetes in the elderly. Sang Thrombose Vaisseaux, 23(8), 409-415.

[2] Wilcox G. Insulin and Insulin Resistance. Clinical Biochemist Reviews. 2005;26(2):19-39.

[3] Muller, D. C., Elahi, D., Tobin, J. D. & Andres, R. Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Aging (Milano) 8, 13–21 (1996).

[4] DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., … & Simonson, D. C. (2015). Type 2 diabetes mellitus. Nature reviews Disease primers, 1, 15019.

[5] Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., … & Lernmark, Å. (2017). Type 1 diabetes mellitus. Nature reviews Disease primers, 3, 17016.

[6] Marchetti, P. et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50, 2486–2494 (2007).

[7] Marchetti, P. & Masini, M. Autophagy and the pancreatic beta-cell in human type 2 diabetes. Autophagy 5, 1055–1056 (2009).

[8] Deng, S. et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53, 624–632 (2004)

[9] Copps, K. D. & White, M. F. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55, 2565–2582 (2012).

[10] Hiratani, K. et al. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS‑1. Biochem. Biophys. Res. Commun. 335, 836–842 (2005)

[11] Krüger, M. et al. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc. Natl Acad. Sci. USA 105, 2451–2456 (2008).

[12] Petersen, K. F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140–1142 (2003).

[13] Romeo, G. R., Lee, J. & Shoelson, S. E. Metabolic syndrome, insulin resistance, and roles of inflammation — mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 32, 1771–1776 (2012).

[14] Herschkovitz, A. et al. Common inhibitory serine sites phosphorylated by IRS‑1 kinases, triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 282, 18018–18027 (2007).

[15] https://infos-diabete.com/diabete/diabete-de-type-2/

[16] DeFronzo, R. A. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773–795 (2009).

[17] Vasavada, R. C. et al. Protein kinase C‑ζ activation markedly enhances β-cell proliferation: an essential role in growth factor mediated β-cell mitogenesis. Diabetes 56, 2732–2743 (2007).

[18] Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333–340 (2013).

[19] Angstadt, Carol N. (4 December 1997). “Purine and Pyrimidine Metabolism: Purine Catabolism”. NetBiochem.

[20] Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47: 610–13.

[21] Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015; 77: 323–45.

[22] Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649–62.

[23] Loeb JN. The infl uence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15: 189–92.

[24] N. Dalbeth, T. R. Merriman, and L. K. Stamp, “Gout,” The Lancet, vol. 388, no. 10055, pp. 2039–2052, 2016.

[25] Taylor WJ, Fransen J, Jansen TL, et al. Study for Updated Gout Classification Criteria (SUGAR): identifi cation of features to classify gout. Arthritis Care Res (Hoboken) 2015; 67: 1304–15.

[26] Aati O, Taylor WJ, Siegert RJ, et al. Development of a patient-reported outcome measure of tophus burden: the tophus impact questionnaire (TIQ-20). Ann Rheum Dis 2015; 74: 2144–50.

[27] Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970; 29: 461–68

[28] Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States : Evidence for a high rate of unexplained anemia. Blood 2004;104:2263-8.

[29] Patel KV. Epidemiology of anemia in older adults. Semin Hematol 2008;45:210-7.

[30] McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10.

[31] Geiger H, Van Zant G. The aging of lympho-hematopoietic stem cells. Nat Immunol 2002;3:329-33.

[32] Emilia Frangos, Kaveh Samii, Jean-Jacques Perrenoud, Ulrich M. Vischer. L’anémie du sujet âgé : une pathologie fréquente à ne pas banaliser. Rev Med Suisse 2010; volume 6.2125–2129.

[33] Lasocki S, Baron G, Driss F, et al. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med 2010;36: 1044-8.

[34] Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999;281:1714-7.

[35] Thein M, Ershler WB, Artz AS, et al. Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore) 2009;88: 107-14.

[36] Zamboni V, Cesari M, Zuccala G, et al. Anemia and cognitive performance in hospitalized older patients : Results from the GIFA study. Int J Geriatr Psychiatry 2006;21:529-34.

[37] Dharmarajan TS, Avula S, Norkus EP. Anemia increases risk for falls in hospitalized older adults : An evaluation of falls in 362 hospitalized, ambulatory, long-term care, and community patients. J Am Med Dir Assoc 2006;7:287-93.